Lutera (levonorgestrel and ethinyl estradiol) Tablets USP, 0.1 mg/0.02 mg, inert tablets, 28-coun...
FDA Drug Recall #D-014-2013 — Class II — October 19, 2012
Recall Summary
| Recall Number | D-014-2013 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 19, 2012 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Watson Laboratories Inc |
| Location | Corona, CA |
| Product Type | Drugs |
| Quantity | 67,860 cartons |
Product Description
Lutera (levonorgestrel and ethinyl estradiol) Tablets USP, 0.1 mg/0.02 mg, inert tablets, 28-count tablets per dispenser packaged in 6 Tablet Dispensers per carton, Rx only, Manufactured by: Watson Laboratories, Inc., Corona, CA 92880 USA; Distributed by: Watson Pharma, Inc., Parsippany, NJ 07054 USA; NDC 52544-949-28.
Reason for Recall
Cross Contamination With Other Products: The firm recalled Zovia, Lutera, Necon, and Zenchent, because certain lots could potentially be contaminated with trace amounts of Hydrochlorothiazide (HCTZ).
Distribution Pattern
Nationwide and Puerto Rico
Lot / Code Information
Lot #: 517921AA, 517921AB, 517922AA, 517922AB, 517923AA, 517923AB, Exp 03/31/14
Other Recalls from Watson Laboratories Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-1053-2014 | Class II | Hydrocodone Bitartrate and Acetaminophen Tablet... | Jan 15, 2014 |
| D-397-2014 | Class II | Carisoprodol Tablets, USP, CIV, 350 mg, 500 cou... | Dec 23, 2013 |
| D-66360-001 | Class II | Next Choice" One Dose Emergency Contraceptive (... | Sep 23, 2013 |
| D-66251-001 | Class II | Oxycodone and Acetaminophen Tablets, USP 10 mg/... | Sep 13, 2013 |
| D-1061-2013 | Class III | Hydrocodone Bitartrate and Acetaminophen Tablet... | Aug 30, 2013 |
Frequently Asked Questions
Injectable drugs and eye drops must be completely free of microbial contamination because they bypass the body's natural defenses. A contaminated injectable can introduce bacteria or fungi directly into the bloodstream, potentially causing sepsis, meningitis, or localized infections — all of which can be life-threatening. Contamination of sterile products almost always results in a Class I recall. If you received an injectable drug from a recalled lot, contact your healthcare provider immediately, even if you feel well, as some infections can have delayed onset.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.